May 4, 2022 -- WCG and Deep 6 AI (artificial intelligence) have joined forces to create a more optimized patient enrollment process for clinical trials. The collaboration will promote optimized patient matching and diversity in clinical trials through WCG’s extensive connections to research sites, sponsors, and contract research organizations alongside Deep 6 AI’s software integration in over 2,000 healthcare facilities serving more than 28 million patients.
The partnership aims to address the prevalent issue of delayed patient enrollment in clinical studies through the creation of comprehensive clinical trial solutions. WCG offers its thorough expertise in the conduct of clinical trials, paired with strong client relationships and site selection capabilities. Deep 6 AI contributes its AI technologies, such as natural language processing and machine learning, which can be used in healthcare facilities to strategically identify patients that qualify as strong matches for specific clinical trials.
The collaboration between these two companies serves to reduce the delays in identification of ideal eligible patients for a clinical study through the use of automation in the setting of a wide network of clinical trial players. As a result, the companies intend to bring novel therapeutics to the market in a more rapid and streamlined process.